KR102001074B1 - Lactobacillus having anticariogenic activities and composition comprising the same - Google Patents
Lactobacillus having anticariogenic activities and composition comprising the same Download PDFInfo
- Publication number
- KR102001074B1 KR102001074B1 KR1020180156663A KR20180156663A KR102001074B1 KR 102001074 B1 KR102001074 B1 KR 102001074B1 KR 1020180156663 A KR1020180156663 A KR 1020180156663A KR 20180156663 A KR20180156663 A KR 20180156663A KR 102001074 B1 KR102001074 B1 KR 102001074B1
- Authority
- KR
- South Korea
- Prior art keywords
- strain
- lactobacillus salivarius
- kctc
- lactobacillus
- accession
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 241000186660 Lactobacillus Species 0.000 title claims abstract description 24
- 229940039696 lactobacillus Drugs 0.000 title claims abstract description 23
- 230000000170 anti-cariogenic effect Effects 0.000 title 1
- 241000186869 Lactobacillus salivarius Species 0.000 claims abstract description 115
- 208000002925 dental caries Diseases 0.000 claims abstract description 37
- 241000194019 Streptococcus mutans Species 0.000 claims abstract description 32
- 208000028169 periodontal disease Diseases 0.000 claims abstract description 29
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 22
- 239000002253 acid Substances 0.000 claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 230000002265 prevention Effects 0.000 claims abstract description 11
- 201000001245 periodontitis Diseases 0.000 claims abstract description 8
- 230000006872 improvement Effects 0.000 claims abstract description 6
- 239000004599 antimicrobial Substances 0.000 claims abstract description 4
- 241000894006 Bacteria Species 0.000 claims description 50
- 239000006228 supernatant Substances 0.000 claims description 28
- 239000003833 bile salt Substances 0.000 claims description 18
- 241000605862 Porphyromonas gingivalis Species 0.000 claims description 8
- 230000028654 Type IV pili-dependent aggregation Effects 0.000 claims description 4
- 230000006806 disease prevention Effects 0.000 claims description 4
- 230000003239 periodontal effect Effects 0.000 claims description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 4
- 239000003613 bile acid Substances 0.000 claims 4
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 210000003785 decidua Anatomy 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 30
- 230000036541 health Effects 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 12
- 235000013376 functional food Nutrition 0.000 abstract description 12
- 239000006041 probiotic Substances 0.000 abstract description 12
- 235000018291 probiotics Nutrition 0.000 abstract description 12
- 210000000941 bile Anatomy 0.000 abstract description 8
- 235000021107 fermented food Nutrition 0.000 abstract description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 52
- 239000004310 lactic acid Substances 0.000 description 26
- 235000014655 lactic acid Nutrition 0.000 description 26
- 239000002609 medium Substances 0.000 description 13
- 244000005700 microbiome Species 0.000 description 10
- 241000186604 Lactobacillus reuteri Species 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000022362 bacterial infectious disease Diseases 0.000 description 5
- 235000013365 dairy product Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- 235000013334 alcoholic beverage Nutrition 0.000 description 4
- 229940093761 bile salts Drugs 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000006872 mrs medium Substances 0.000 description 4
- 235000012149 noodles Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 241000721662 Juniperus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000015140 cultured milk Nutrition 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 102000000340 Glucosyltransferases Human genes 0.000 description 2
- 108010055629 Glucosyltransferases Proteins 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000193987 Streptococcus sobrinus Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000013527 bean curd Nutrition 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- -1 olive oil Chemical compound 0.000 description 2
- 235000013550 pizza Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001135221 Prevotella intermedia Species 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- 241000194008 Streptococcus anginosus Species 0.000 description 1
- 241000194043 Streptococcus criceti Species 0.000 description 1
- 241000194026 Streptococcus gordonii Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 241000194052 Streptococcus ratti Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000589892 Treponema denticola Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/312—Foods, ingredients or supplements having a functional effect on health having an effect on dental health
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 인체 및 다양한 발효식품 유래 락토바실러스 살리바리우스 및 락토바실러스 루테리를 포함하는 충치균 또는 치주염균 억제용 항균 조성물, 치아 우식증 또는 치주질환 예방, 치료, 개선용 약학적 조성물, 건강기능식품 조성물 및 의약외품 조성물에 관한 것이다. 본 발명의 락토바실러스 살리바리우스 MG4293 균주 및 락토바실러스 살리바리우스 MG4527 균주는 스트렙토코쿠스 뮤탄스 또는 포르리로모나스 진지발린스 억제 활성이 뛰어나며, 내산성, 내담즙성 및 자가 응집능이 뛰어나 프로바이오틱스에 적합하므로, 충치 예방, 치료 또는 개선을 위한 의약품, 식품, 의약외품 등으로 다양하게 활용될 수 있다. The present invention relates to an antimicrobial composition for inhibiting cavities or periodontitis comprising Lactobacillus salivarius and Lactobacillus lutei derived from human and various fermented foods, a pharmaceutical composition for preventing, treating or improving dental caries or periodontal disease, a health functional food composition and a quasi-drug ≪ / RTI > The Lactobacillus salivarius strain MG4293 and Lactobacillus salivarius MG4527 strain of the present invention are excellent in the inhibitory activity against streptococcus mutans or forrilluminas spring rinse and are excellent in acid resistance, bile resistance and self-aggregating ability and are suitable for probiotics, It can be used variously for medicines, foods, quasi-drugs for prevention, treatment or improvement.
Description
본 발명은 인체 및 다양한 발효식품 유래 락토바실러스 살리바리우스 및 락토바실러스 루테리를 포함하는 충치균 또는 치주염균 억제용 항균 조성물, 치아 우식증 또는 치주질환 예방, 치료, 개선용 약학적 조성물, 건강기능식품 조성물 및 의약외품 조성물에 관한 것이다. The present invention relates to an antimicrobial composition for inhibiting cavities or periodontitis comprising Lactobacillus salivarius and Lactobacillus lutei derived from human and various fermented foods, a pharmaceutical composition for preventing, treating or improving dental caries or periodontal disease, a health functional food composition and a quasi-drug ≪ / RTI >
유산균은 특별한 생리활성능력을 가지고 있으며, 일반적으로 안전한 균주 (GRAS, generally regarded as safe bacteria)로 취급되고 있다. 유산균은 다양한 발효식품의 생산에 사용하고 있을 뿐만 아니라, 기능성과 프로바이오틱스 특성을 가지는 유제품과 발효과채 제품에 널리 사용되고 있다. 최근에는 화학보조제를 대체하는 천연보조제에 대한 소비자의 수요가 증가함에 따라 그 대안방안으로 부각되고 있다. 프로바이오틱스는 숙주동물의 건강에 매우 유익한 효과를 주는 살아있는 미생물로, 장내 미생물의 균형을 개선하고 영양분의 흡수를 증진시킨다. 또한, 프로바이오틱스는 장내환경에서 병원성미생물의 항균작용을 나타내는 특성을 가지고 있다. 프로바이오틱스에는 다양한 미생물이 포함되지만, 락토바실러스(Lactobacillus) 속과 비피도박테리움(Bifidobacterium) 속이 가장 많은 분포를 차지하고 있다. 특히, 락토바실러스(Lactobacillus) 속은 일반적으로 유제품, 육류, 과채 및 시리얼 제품의 발효공정에 사용되고 있다. Lactic acid bacteria have a specific physiological activity and are generally regarded as safe strains (GRAS). Lactic acid bacteria are used not only for the production of various fermented foods, but also for dairy products and fermented fruit and vegetable products having functional and probiotic characteristics. In recent years, as consumers' demand for natural adjuvants to replace chemical adjuvants has increased, they have become an alternative. Probiotics are living microorganisms that have a very beneficial effect on the health of host animals, improving the balance of intestinal microorganisms and promoting uptake of nutrients. In addition, probiotics are characteristic of antibiotic action of pathogenic microorganisms in intestinal environment. Probiotics include a variety of microorganisms, but Lactobacillus , Genus Bifidobacterium < RTI ID = 0.0 > The genus occupies the most distribution. In particular, the genus Lactobacillus (Lactobacillus) are generally used in the dairy, meat, and gwachae fermentation of cereal products.
한편, 사람의 구강에는 400종류 이상의 세균이 번식하고 있으며, 그 균수는 100억 개에 달하고 타액에는 108∼109 CFU/㎖ 수준의 균이 존재하는 것으로 알려져 있다. 치아는 미세한 구멍이 다수개 천공되어 있어서 충치를 일으키는 세균이 천공된 구멍으로 들어가 치아를 병들게 하는데 이것이 충치이다. 이러한 충치는 치아에서 가장 흔히 볼 수 있는 대표적인 질환의 하나로 치아우식증이라고도 한다. 충치는 구강 내 음식물이 내산성 연쇄상구균과 유산균에 의해 부패되고 산에 의해 치아의 성분이 파괴되는 감염성 세균성 질환으로, 치석 (plaque)내 미생물과 음식물의 상호작용으로 발생되는 다인성 질환이다. 미생물 중에서 스트렙토코쿠스 뮤탄스 (Streptococcus mutans) 가 치석의 주요 원인균이며, 이 미생물은 치면의 피막에 부착한 후 생성하는 클루코실트랜스퍼라아제 (glucosyltransferase, GTase)에 의하여 음식물 중의 수크로오즈로부터 불용성 글루칸을 합성한다. 합성된 글루칸은 치면에서 증식하는 미생물 간의 결합을 증가시키며, 치면에 부착한 S. mutans는 당질 대사과정에서 젖산 등의 유기산을 생성하여 치아의 에나멜질을 탈회 (decalcification) 시켜 충치를 유발하는 것으로 알려져 있다. 우리나라에서는 영구 치아의 충치 이환율이 약 80%에 이르고, 한 사람이 평균 2-3개의 충치를 가지고 있는 것으로 보고되고 있다.On the other hand, more than 400 kinds of bacteria are propagated in human oral cavity, and the number of bacteria is 10 billion, and saliva is known to have a level of 10 8 to 10 9 CFU / ml. The teeth have a number of fine holes, so bacteria that cause cavities enter the perforated holes and cause toothache. This is tooth decay. Such tooth decay is one of the most common dental diseases and is also called dental caries. Tooth decay is a multifactorial disease caused by the interaction of microbes and food in the plaque, which is an infectious bacterial disease in which oral food is corrupted by acid-fast streptococci and lactic acid bacteria, and the teeth are destroyed by acid. Among the microorganisms, Streptococcus mutans is a major causative agent of calculus. This microorganism is formed from glucosyltransferase (GTase), which is formed after adhering to the surface of the tooth surface, from sucrose in food to insoluble glucan . The synthesized glucan increases the binding between the microorganisms growing on the tooth surface. The S. mutans attached to the tooth surface is known to generate organic acids such as lactic acid in the saccharide metabolism process and decalcify the tooth enamel to induce cavities have. In Korea, tooth decay rate of permanent teeth is about 80%, and it is reported that one person has 2-3 cavities on average.
종래의 치아우식증 또는 치주질환 예방 방법으로는 칫솔질과 적절한 식이 요법을 통해 당분의 섭취를 줄이거나 자일리톨을 이용하여 충치균 또는 치주질환 유발균에 의한 산의 생성을 방지하는 방법 등이 있으나, 이러한 방법만으로는 충치 유발균 또는 치주질환 유발균의 사멸을 통한 근본적인 충치 예방효과를 얻지 못하고 있는 실정이다. Conventional dental caries prevention or periodontal disease prevention methods include reduction of sugar intake through brushing and proper dieting, or prevention of acid production by tooth decay bacteria or periodontal disease inducing bacteria using xylitol. It has not been able to obtain a fundamental effect of preventing tooth decay through the death of the tooth decay bacteria or periodontal disease inducers.
따라서 인체에 무해한 인체 또는 식품 유래의 유산균을 이용하여 인체에 무해하고 섭취가 용이하며, 충치 유발균 또는 치주질환 유발균의 생육을 직접적으로 억제하는 새로운 충치 예방 방법에 대한 필요성이 있다. Therefore, there is a need for a new tooth decay prevention method that directly inhibits the growth of tooth decay bacteria or periodontal disease-causing microorganisms by harmless human body or food-derived lactic acid bacterium which is harmless to the human body and is harmless to the human body and easy to ingest.
삭제delete
이에 본 발명자들은 인체 및 식품 유래의 유산균 중 충치 예방에 효과가 있는 유산균에 대하여 연구하던 중, 락토바실러스 살리바리우스 MG4293 균주 (기탁번호: KCTC 13727BP) 및 락토바실러스 살리바리우스 MG4527 균주 (기탁번호: KCTC 13728BP)가 충치 유발균인 스트렙토코쿠스 뮤탄스 및 치주염균인 포르리로모나스 진지발린스에 대한 항균 효과가 뛰어나며, 내산성, 내담즙성 및 자가 응집능이 뛰어나 프로바이오틱스로 유용함을 확인하고 본 발명을 완성하였다. Accordingly, the inventors of the present invention have been studying lactic acid bacteria that are effective in preventing tooth decay among human and food-derived lactic acid bacteria. Lactobacillus salivarius MG4293 (Accession No .: KCTC 13727BP) and Lactobacillus salivarius MG4527 (Accession No .: KCTC 13728BP ) Was excellent in antimicrobial effect against streptococcus mutans which is a tooth decaying bacteria and Poriromonas jinguji rinse which is a periodontitis germ, and was excellent in acid resistance, bile resistance and self-aggregation ability, and was proved to be useful as probiotics.
따라서 본 발명의 목적은 락토바실러스 살리바리우스 MG4293 균주 (기탁번호: KCTC 13727BP) 및 락토바실러스 살리바리우스 MG4527 균주 (기탁번호: KCTC 13728BP) 로 이루어진 군에서 선택된 1종 이상의 균주, 이의 배양액 또는 이의 무세포 상등액을 포함하는 충치균 또는 치주염균 억제용 항균 조성물 및 이를 이용한 치아우식증 또는 치주질환 예방, 치료, 개선용 조성물을 제공하는 것이다. Accordingly, an object of the present invention is to provide a culture solution of the Lactobacillus salivarius MG4293 strain (accession number: KCTC 13727BP) and a strain of Lactobacillus salivarius MG4527 (accession number: KCTC 13728BP), a culture thereof or a cell- And to provide a composition for preventing, treating or ameliorating dental caries or periodontal disease using the antimicrobial composition.
상기 목적을 달성하기 위하여, 본 발명은 락토바실러스 살리바리우스 MG4293 균주 (기탁번호: KCTC 13727BP) 및 락토바실러스 살리바리우스 MG4527 균주 (기탁번호: KCTC 13728BP) 로 이루어진 군에서 선택된 1종 이상의 균주, 이의 배양액 또는 이의 무세포 상등액을 포함하는 충치균 또는 치주염균 억제용 항균 조성물을 제공한다. In order to achieve the above object, the present invention provides a method for producing a microorganism, which comprises culturing at least one strain selected from the group consisting of Lactobacillus salivarius MG4293 strain (accession number: KCTC 13727BP) and Lactobacillus salivarius MG4527 strain (accession number: KCTC 13728BP) And an anticancer composition containing the cell-free supernatant.
또한 본 발명은 락토바실러스 살리바리우스 MG4293 균주 (기탁번호: KCTC 13727BP) 및 락토바실러스 살리바리우스 MG4527 균주 (기탁번호: KCTC 13728BP) 로 이루어진 군에서 선택된 1종 이상의 균주, 이의 배양액 또는 이의 무세포 상등액을 포함하는 치아 우식증 또는 치주질환 예방 또는 치료용 약학적 조성물을 제공한다. The present invention also encompasses one or more strains selected from the group consisting of Lactobacillus salivarius MG4293 strain (Accession No .: KCTC 13727BP) and Lactobacillus salivarius MG4527 strain (Accession No: KCTC 13728BP), a culture thereof or a cell-free supernatant thereof Or a periodontal disease or a periodontal disease.
또한 본 발명은 락토바실러스 살리바리우스 MG4293 균주 (기탁번호: KCTC 13727BP) 및 락토바실러스 살리바리우스 MG4527 균주 (기탁번호: KCTC 13728BP) 로 이루어진 군에서 선택된 1종 이상의 균주, 이의 배양액 또는 이의 무세포 상등액을 포함하는 치아 우식증 또는 치주질환 예방 또는 개선용 건강기능식품 조성물을 제공한다. The present invention also encompasses one or more strains selected from the group consisting of Lactobacillus salivarius MG4293 strain (Accession No .: KCTC 13727BP) and Lactobacillus salivarius MG4527 strain (Accession No: KCTC 13728BP), a culture thereof or a cell-free supernatant thereof A dental caries prevention or periodontal disease prevention or improvement.
또한 본 발명은 락토바실러스 살리바리우스 MG4293 균주 (기탁번호: KCTC 13727BP) 및 락토바실러스 살리바리우스 MG4527 균주 (기탁번호: KCTC 13728BP) 로 이루어진 군에서 선택된 1종 이상의 균주, 이의 배양액 또는 이의 무세포 상등액을 포함하는 치아 우식증 또는 치주질환 예방 또는 개선용 의약외품 조성물을 제공한다. The present invention also encompasses one or more strains selected from the group consisting of Lactobacillus salivarius MG4293 strain (Accession No .: KCTC 13727BP) and Lactobacillus salivarius MG4527 strain (Accession No: KCTC 13728BP), a culture thereof or a cell-free supernatant thereof And a quasi-drug composition for preventing or ameliorating periodontal disease.
본 발명의 락토바실러스 살리바리우스 MG4293 균주 및 락토바실러스 살리바리우스 MG4527 균주는 스트렙토코쿠스 뮤탄스 및 포르리로모나스 진지발린스 억제 활성이 뛰어나며, 내산성, 내담즙성 및 자가 응집능이 뛰어나 프로바이오틱스에 적합하므로, 치아 우식증 또는 치주질환 예방, 치료 또는 개선을 위한 의약품, 식품, 의약외품 등으로 다양하게 활용될 수 있다. The Lactobacillus salivarius MG4293 strain and Lactobacillus salivarius MG4527 strain of the present invention are excellent in inhibitory activity against streptococcus mutans and porry lomonus juniper rinse and are excellent in acid resistance, bile resistance and self-aggregation ability and are suitable for probiotics, It can be used variously as medicine, food, quasi-drug for prevention, treatment or improvement of caries or periodontal disease.
도 1은 락토바실러스 살리바리우스 MG242 및 락토바실러스 루테리 MG505, 락토바실러스 살리바리우스 MG4293, 락토바실러스 살리바리우스 MG4527, 락토바실러스 살리바리우스 MG5183 균주의 배양액 (Cell mixture), 무세포 상등액 (CFS mixture) 의 S. mutans 억제 활성을 확인한 결과를 나타낸 도이다.
도 2는 락토바실러스 살리바리우스 MG242 및 락토바실러스 루테리 MG505, 락토바실러스 살리바리우스 MG4293, 락토바실러스 살리바리우스 MG4527, 락토바실러스 살리바리우스 MG5183 균주의 자가 응집능을 확인한 결과를 나타낸 도이다.
도 3은 락토바실러스 살리바리우스 MG242, 락토바실러스 루테리 MG505, 락토바실러스 살리바리우스 MG4293, 락토바실러스 살리바리우스 MG4527, 락토바실러스 살리바리우스 MG5183 균주의 혼합 CFS, 세포 혼합 배양액 및 CFS와 세포 혼합 배양액의 S. mutans 억제 효과를 나타낸 도이다. Brief Description of the Drawings Fig. 1 is a graph showing the cell mixture of Lactobacillus salivarius MG242 and Lactobacillus luterian MG505, Lactobacillus salivarius MG4293, Lactobacillus salivarius MG4527 and Lactobacillus salivarius MG5183, S. mutans of a CFS mixture Lt; / RTI >
FIG. 2 is a graph showing the results of confirming the self-aggregating ability of Lactobacillus salivarius MG242, Lactobacillus luterian MG505, Lactobacillus salivarius MG4293, Lactobacillus salivarius MG4527, and Lactobacillus salivarius MG5183.
3 is Lactobacillus salivarius MG242, MG505 ruteri Lactobacillus, Lactobacillus salivarius MG4293, MG4527 Lactobacillus salivarius, Lactobacillus salivarius strain MG5183 mixture of CFS, cell culture medium and mixed with CFS cells mixed culture of S. mutans FIG.
본 발명은 락토바실러스 살리바리우스 MG4293 균주 (기탁번호: KCTC 13727BP) 및 락토바실러스 살리바리우스 MG4527 균주 (기탁번호: KCTC 13728BP) 로 이루어진 군에서 선택된 1종 이상의 균주, 이의 배양액 또는 이의 무세포 상등액을 포함하는 충치균 또는 치주염균 억제용 항균 조성물을 제공한다. The present invention relates to a culture medium containing at least one strain selected from the group consisting of Lactobacillus salivarius MG4293 strain (accession number: KCTC 13727BP) and Lactobacillus salivarius MG4527 strain (accession number: KCTC 13728BP), a culture thereof or a cell- The present invention provides an antimicrobial composition for inhibiting tooth decay bacteria or periodontitis bacteria.
본 발명의 락토바실러스 살리바리우스 MG4293 균주 및 락토바실러스 살리바리우스 MG4527 균주는 스트렙토코쿠스 뮤탄스 및/또는 포르리로모나스 진지발린스 억제 활성이 뛰어나며, 내산성, 내담즙성 및 자가 응집능이 뛰어나다. The Lactobacillus salivarius MG4293 strain and Lactobacillus salivarius MG4527 strain of the present invention are excellent in the inhibitory activity against Streptococcus mutans and / or Porirromonas juniper rinse, and are excellent in acid resistance, bile resistance and self-aggregating ability.
이하, 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명에서 용어, "락토바실러스"는 자연계에 널리 분포하는 당류를 발효하여 에너지를 획득하여 다량의 유산을 생성하는 세균으로 형태적으로는 그람 양성 무포자 간균으로 다형성을 나타낸다. 본 발명에 따른 스트렙토코쿠스 뮤탄스 및/또는 포르리로모나스 진지발린스 억제 활성이 뛰어나며, 내산성, 내담즙성 및 자가 응집능이 뛰어난 락토바실러스 살리바리우스 MG4293 및 락토바실러스 살리바리우스 MG4527 균주는 각각 한국생명공학연구원에 기탁하여 기탁번호 KCTC 13727BP 및 KCTC 13728BP 를 부여받았다.In the present invention, the term "lactobacillus" refers to a bacterium which is fermented by a widely distributed saccharide in nature and produces energy to obtain a large amount of lactic acid, and is morphologically polymorphic as gram-positive spore bacillus. Lactobacillus salivarius MG4293 and Lactobacillus salivarius MG4527, which are excellent in the inhibitory activity against Streptococcus mutans and / or Porirromonas juniper rinse according to the present invention and excellent in acid resistance, bile resistance and self-aggregating ability, KCTC 13727BP and KCTC 13728BP, respectively.
또한 본 발명의 조성물은 스트렙토코쿠스 뮤탄스 및/또는 포르리로모나스 진지발린스 억제 활성, 내산성, 내담즙성 및 자가 응집능을 갖는 또다른 균주인 락토바실러스 루테리 MG505, 락토바실러스 살리바리우스 MG242 및 락토바실러스 살리바리우스 MG5183 로 이루어진 군에서 선택된 1종 이상의 균주, 이의 배양액 또는 이의 무세포 상등액을 더 포함할 수 있으며, 락토바실러스 루테리 MG505, 락토바실러스 살리바리우스 MG242 및 락토바실러스 살리바리우스 MG5183 는 각각 한국생명공학연구원에 기탁하여 기탁번호 KCTC 13523BP, KCTC 18554P 및 KCTC 13729BP를 부여받았다. In addition, the composition of the present invention is also useful as a further strain having Streptococcus mutans and / or Porirromonas juice rinse inhibitory activity, acid resistance, biliary and self-aggregating ability, Lactobacillus luteri MG505, Lactobacillus salivarius MG242, Bacillus salivarius MG5183, a culture solution thereof, or a cell-free supernatant thereof. Lactobacillus luterium MG505, Lactobacillus salivarius MG242 and Lactobacillus salivarius MG5183 may be further added to the culture medium of Korean Biotechnology Research Institute To receive the deposit numbers KCTC 13523BP, KCTC 18554P and KCTC 13729BP.
본 발명에 있어, 상기 락토바실러스 살리바리우스 MG4293, 락토바실러스 살리바리우스 MG4527 및 락토바실러스 루테리 MG505 균주는 대표적인 충치 세균인 스트렙토코쿠스 뮤탄스 및 포르리로모나스 진지발린스 모두에 대하여 우수한 항균 활성을 나타낼 뿐만 아니라, 우수한 내산성 및 내담즙성을 가지는 것을 특징으로 한다. 보다 구체적으로 락토바실러스 살리바리우스 MG4293, 락토바실러스 살리바리우스 MG4527 및 락토바실러스 루테리 MG505 균주는 강산 조건인 pH 2 내지 4, 더욱 바람직하게는 위산 환경인 pH2 에서 매우 높은 생존율을 유지할 수 있다. In the present invention, the Lactobacillus salivarius MG4293, Lactobacillus salivarius MG4527, and Lactobacillus luterian MG505 strain exhibit excellent antimicrobial activity against both of the typical caries bacterium Streptococcus mutans and Porirromonas jinja rinse , And has excellent acid resistance and brittleness. More specifically, Lactobacillus salivarius MG4293, Lactobacillus salivarius MG4527 and Lactobacillus luterian MG505 strain can maintain a very high survival rate at pH 2 to 4, which is a strong acid condition, and more preferably pH 2, which is a gastric environment.
또한 본 발명의 락토바실러스 살리바리우스 MG242 및 락토바실러스 루테리 MG505, 락토바실러스 살리바리우스 MG4293, 락토바실러스 살리바리우스 MG4527, 락토바실러스 살리바리우스 MG5183 균주는 장내 환경과 유사한 담즙염에 대하여 내담즙성을 갖고, 0.1 내지 1.5% 담즙염, 0.3 내지 1% 의 담즙염, 바람직하게는 1% 의 담즙염에서도 우수한 내성을 나타낼 수 있다. The Lactobacillus salivarius MG242 and Lactobacillus luterian MG505, Lactobacillus salivarius MG4293, Lactobacillus salivarius MG4527 and Lactobacillus salivarius MG5183 strain of the present invention have bile bile resistance against bile salts similar to intestinal environment, 1.5% bile salt, 0.3-1% bile salt, preferably 1% bile salt.
본 발명의 락토바실러스 살리바리우스 MG242 및 락토바실러스 루테리 MG505, 락토바실러스 살리바리우스 MG4293, 락토바실러스 살리바리우스 MG4527, 락토바실러스 살리바리우스 MG5183 균주는 우수한 자가응집능(autoaggregation ability)을 나타내어 장의 연축운동에 의한 프로바이오틱스의 제거를 방지할 수 있으며, 특히 락토바실러스 살리바리우스 MG4293, 락토바실러스 살리바리우스 MG4527 균주는 매우 우수한 자가응집능을 나타낼 수 있다. The Lactobacillus salivarius MG242 and Lactobacillus luterian MG505, Lactobacillus salivarius MG4293, Lactobacillus salivarius MG4527 and Lactobacillus salivarius MG5183 strain of the present invention exhibit excellent autoaggregation ability and exhibit excellent autoaggregation ability of the probiotic In particular, Lactobacillus salivarius MG4293 and Lactobacillus salivarius MG4527 strain can exhibit excellent self-aggregating ability.
또한 본 발명은 락토바실러스 살리바리우스 MG4293 균주 (기탁번호: KCTC 13727BP) 및 락토바실러스 살리바리우스 MG4527 균주 (기탁번호: KCTC 13728BP) 로 이루어진 군에서 선택된 1종 이상의 균주, 이의 배양액 또는 이의 무세포 상등액을 포함하는 치아 우식증 또는 치주 질환 예방 또는 치료용 약학적 조성물, 건강기능식품 조성물, 식품 조성물, 의약외품조성물을 제공한다. The present invention also encompasses one or more strains selected from the group consisting of Lactobacillus salivarius MG4293 strain (Accession No .: KCTC 13727BP) and Lactobacillus salivarius MG4527 strain (Accession No: KCTC 13728BP), a culture thereof or a cell-free supernatant thereof A dental caries prevention or periodontal disease prevention or treatment, a health functional food composition, a food composition, and a quasi-drug composition.
상기 약학적 조성물, 건강기능식품 조성물, 식품 조성물, 의약외품 조성물은 유효성분으로서 락토바실러스 살리바리우스 MG4293 균주 (기탁번호: KCTC 13727BP) 및 락토바실러스 살리바리우스 MG4527 균주 (기탁번호: KCTC 13728BP) 로 이루어진 군에서 선택된 1종 이상의 균주, 이의 배양액 또는 이의 무세포 상등액을 를 포함할 수 있으며, 락토바실러스 루테리 MG505 (기탁번호: KCTC 13523BP), 락토바실러스 살리바리우스 MG242 (기탁번호: KCTC 18554P) 및 락토바실러스 살리바리우스 MG5183 (기탁번호: KCTC 13729BP)로 이루어진 군에서 선택된 1종 이상의 균주, 이의 배양액 또는 이의 무세포 상등액을 더 포함 할 수 있다. The pharmaceutical composition, the health functional food composition, the food composition and the quasi-drug composition according to the present invention are effective as the active ingredient in the group consisting of Lactobacillus salivarius MG4293 strain (Accession No .: KCTC 13727BP) and Lactobacillus salivarius MG4527 strain (Accession No. KCTC 13728BP) (Accession number: KCTC 13523BP), Lactobacillus salivarius MG242 (accession number: KCTC 18554P), and Lactobacillus salivarius MG5183 (accession number: KCTC 18554P), or a cell-free supernatant thereof, (Accession No .: KCTC 13729BP), a culture thereof or a cell-free supernatant thereof.
약학적 조성물의 경우, 상기 균주들은 약학적 조성물 총 100 중량부에 대하여 0.01~95 중량부로 포함되는 것이 바람직하며, 더욱 바람직하게는 1~80 중량부로 포함하는 것이다. 그 함량이 0.01 중량부 미만일 경우에는 복용 효율성이 떨어질 수 있으며, 95 중량부를 초과할 경우에는 제형화에 어려움이 있을 수 있다.In the case of a pharmaceutical composition, the above-mentioned strains are preferably contained in an amount of 0.01 to 95 parts by weight, more preferably 1 to 80 parts by weight, based on 100 parts by weight of the total amount of the pharmaceutical composition. When the content is less than 0.01 part by weight, the efficiency of taking may be lowered, and when it is more than 95 parts by weight, it may be difficult to formulate.
본 발명에 따른 락토바실러스 살리바리우스 MG242, 락토바실러스 루테리 MG505, 락토바실러스 살리바리우스 MG4293, 락토바실러스 살리바리우스 MG4527, 및 락토바실러스 살리바리우스 MG5183 균주는 충치 유발 세균 및 치주염균에 대하여 우수한 항균 활성을 갖고, 내산성, 내담즙성, 자가 응집력이 우수하므로, 충치 균 및 치주염균에 의해 유발되는 다양한 질환의 예방, 개선 또는 치료 효과를 가진 조성물 자체로서 직접적으로 사용 가능함은 물론이고, 보조제로서 사용할 수도 있다.The Lactobacillus salivarius MG242, Lactobacillus luterian MG505, Lactobacillus salivarius MG4293, Lactobacillus salivarius MG4527, and Lactobacillus salivarius MG5183 strain according to the present invention have excellent antibacterial activity against the cavitation-inducing bacteria and periodontal bacteria, , Biliary properties, and self-cohesion, it can be directly used as a composition itself having an effect of preventing, ameliorating or treating various diseases caused by caries bacteria and periodontitis bacteria, and can also be used as an adjuvant.
본 발명에 따른 약학적 조성물은 약학적으로 유효한 양의 락토바실러스 살리바리우스 MG242, 락토바실러스 루테리 MG505, 락토바실러스 살리바리우스 MG4293, 락토바실러스 살리바리우스 MG4527, 또는 락토바실러스 살리바리우스 MG5183 균주를 단독으로 포함하거나 하나 이상의 약학적으로 허용되는 담체, 부형제 또는 희석제를 포함할 수 있다. The pharmaceutical composition according to the present invention may comprise a pharmaceutically effective amount of Lactobacillus salivarius MG242, Lactobacillus ruteri MG505, Lactobacillus salivarius MG4293, Lactobacillus salivarius MG4527, or Lactobacillus salivarius MG5183 alone or in combination with one Or a pharmaceutically acceptable carrier, excipient or diluent.
치아우식증 및 치주질환은 모두 세균 감염성 질환으로 치아우식증은 스트렙토코커스 뮤탄스(S. mutans), 스트렙토코커스 상퀴니스(S. sanguinis), 스트렙토코커스 소브리누스(S. sobrinus), 스트렙토코커스 라티(S. ratti), 스트렙토코커스 크리세티(S. criceti), 스트렙토코커스 안지노수스(S. anginosus) 또는 스트렙토코커스 고도니(S. gordonii) 와 같은 균에 의해서, 치주질환은 치주염을 유발하는 세균인 포피로모나스 긴지발리스(Porphyromonas gingivalis), 프리보텔라 인터미디아(Prevotella intermedia), 악티노바실러스 악티티노미세템코미탄스(Actinobacillus actinomycetemcomitans), 트레포네마 덴티콜라(Treponema denticola) 및 푸소박테리움 누클리아툼(Fusobacterium nucleatum) 등에 의해서 유발될 수 있다. 본 발명에 따른 약학적 조성물은 대표적인 치아 우식증 및 치주질환 유발균을 효과적으로 억제할 수 있으므로 치아우식증 또는 치주질환의 예방 또는 치료에 매우 효과적이다. Dental caries and periodontal disease are all bacterial infectious diseases. Dental caries is caused by S. mutans , S. sanguinis , S. sobrinus , Streptococcus latae (Streptococcus lactis by bacteria such as S. ratti), Streptococcus Cri Shetty (S. criceti), Streptococcus not Gino Versus (S. anginosus) or Streptococcus highly Needle (S. gordonii), periodontal disease is the bacteria that causes periodontal disease Porphyromonas gingivalis , Prevotella intermedia , Actinobacillus actinomycetemcomitans , Treponema denticola , and Fusobacterium nuclideum. nucleatum ) and the like. The pharmaceutical composition according to the present invention can effectively inhibit typical dental caries and periodontal disease-inducing bacteria, and thus is highly effective in preventing or treating dental caries or periodontal disease.
따라서 상기에서 "약학적으로 유효한 양"이란, 예컨대 충치 유발 및 치주염 유발 세균인 스트렙토코쿠스 뮤탄스 및 포르리로모나스 진지발린스의 생육을 억제하여 이로 인해 발생할 수 있는 치아 우식증 또는 치주질환의 예방, 개선 또는 치료 효과를 발휘하기에 충분한 양을 말한다. 상기 "약학적으로 허용되는"이란, 생리학적으로 허용되고 인간에게 투여될 때, 통상적으로 위장 장애, 현기증과 같은 알레르기 반응 또는 이와 유사한 반응을 일으키지 않는 조성물을 말한다.Therefore, the term "pharmaceutically effective amount" as used herein refers to an amount of a compound capable of inhibiting the growth of streptococcus mutans and porryromonas jinju rinse, which are, for example, caries-inducing and periodontitis-inducing bacteria and preventing or preventing dental caries or periodontal disease, Quot; refers to an amount sufficient to exert an improvement or therapeutic effect. The phrase "pharmaceutically acceptable " as used herein refers to a composition that is physiologically acceptable and does not normally cause an allergic reaction such as gastrointestinal disorder, dizziness, or the like when administered to a human.
또한 본 발명에 따른 약학적 조성물은 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 당해 기술 분야에 알려진 적합한 제제는 문헌(Remington's Pharmaceutical Science, 최근, Mack Publishing Company, Easton PA)에 개시되어 있는 것을 사용하는 것이 바람직하다. 포함될 수 있는 담체, 부형제 및 희석제로는 락토오스, 덱스트로오스, 수크로오스, 소르비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시 벤조에이트, 프로필히드록시 벤조에이트, 탈크, 마그네슘 스테아레이트, 광물유 등이 있다. 상기 약학적 조성물을 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 조성물에 적어도 하나 이상의 부형제, 예를 들면 전분, 칼슘 카보네이트(calcium carbonate), 수크로오스, 락토오스, 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제 등이 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. The pharmaceutical composition according to the present invention may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to a conventional method . Suitable formulations known in the art are preferably those as disclosed in Remington ' s Pharmaceutical Science, recently, Mack Publishing Company, Easton PA. Examples of carriers, excipients and diluents which may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, Cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like. When the pharmaceutical composition is formulated, it is prepared using a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or an excipient usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose, Gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
본 발명의 약학적 조성물은 연구자, 수의사, 의사 또는 기타 임상에 의해 생각되는 조직계, 동물 또는 인간에서 생물학적 또는 의학적 반응을 유도하는 유효 성분 또는 약학적 조성물의 양, 즉 치료되는 질환 또는 장애의 증상의 완화를 유도하는 양인 치료상 유효량으로 투여할 수 있다. 본 발명의 약학적 조성물에 대한 치료상 유효 투여량 및 투여횟수는 원하는 효과에 따라 변화될 것임은 당업자에게 자명하다. 그러므로, 투여될 최적의 투여량은 당업자에 의해 쉽게 결정될 수 있으며, 질환의 종류, 질환의 중증도, 조성물에 함유된 유효성분 및 다른 성분의 함량, 제형의 종류, 및 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여시간, 투여 경로 및 조성물의 분비율, 치료기간, 동시 사용되는 약물을 비롯한 다양한 인자에 따라 조절될 수 있다. 바람직한 효과를 위해서, 본 발명의 약학적 조성물은 1~10,000㎎/㎏/day, 바람직하게는 1~200㎎/㎏/day의 양으로 투여할 수 있으며, 하루에 한번 투여할 수도 있고, 수 회에 나누어 투여할 수도 있다. The pharmaceutical composition of the present invention is useful as an effective ingredient or amount of a pharmaceutical composition that induces a biological or medical response in a tissue system, an animal or a human, as considered by a researcher, veterinarian, physician or other clinician, Or a therapeutically effective amount which is sufficient to induce relief. It will be apparent to those skilled in the art that the therapeutically effective dose and the frequency of administration for the pharmaceutical compositions of the present invention will vary with the desired effect. Thus, the optimal dosage to be administered can be readily determined by those skilled in the art and will vary with the nature of the disease, the severity of the disease, the amount of active and other ingredients contained in the composition, the type of formulation, and the age, The age, body weight, sex, diet, time of administration, route of administration and fraction of the composition, duration of treatment, concurrent medication, and the like. For a desired effect, the pharmaceutical composition of the present invention may be administered in an amount of 1 to 10,000 mg / kg / day, preferably 1 to 200 mg / kg / day, or may be administered once a day, . ≪ / RTI >
본 발명의 약학적 조성물은 개체에게 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 주사에 의해 투여될 수 있다. The pharmaceutical composition of the present invention may be administered to a subject in various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.
본 발명에 따른 약학적 조성물은 단독으로 사용될 수 있으나, 통상의 기술자의 선택에 따라 통상적으로 치아우식증 또는 치주질환의 치료 증강 효과가 있는 적절한 기타 치료 방법(예컨대, 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제 이용 방법 등)과 병용하여 사용할 수 있다.The pharmaceutical composition according to the present invention may be used singly, but it may be administered to a patient in need of other appropriate treatment methods (for example, surgery, radiation therapy, hormone therapy, chemotherapy Treatment and use of a biological response modifier, etc.).
본 발명에서 용어, "예방"이란, 본 발명에 따른 치아 우식증 또는 치주질환의 예방 또는 치료용 조성물을 개체에 투여하여 치아 우식증 또는 치주질환의 발병을 억제하거나 지연시키는 모든 행위를 의미할 수 있다.In the present invention, the term "prevention" may mean all actions that inhibit or delay the onset of dental caries or periodontal disease by administering to a subject a composition for preventing or treating periodontal disease or periodontal disease according to the present invention.
본 발명에서 용어, "치료"란, 본 발명에 따른 조성물을 치아 우식증 또는 치주질환 의심 개체에 투여하여 치아 우식증 또는 치주질환 관련 질환의 증세가 호전되도록 하거나 이롭게 되도록 하는 모든 행위를 의미할 수 있다.The term "treatment" in the present invention means all the actions for improving or alleviating the symptoms of dental caries or periodontal disease by administering the composition according to the present invention to dental caries or suspected periodontal disease suspects.
본 발명에서 용어, "개선"은 치료되는 상태와 관련된 파라미터, 예를 들면 증상의 정도를 적어도 감소시키는 모든 행위를 의미할 수 있다.As used herein, the term "improvement" may mean any action that at least reduces the degree of symptom associated with the condition being treated.
본 발명에서 용어, "개체"란, 치아 우식증 또는 치주질환이 발병되었거나 발병할 가능성이 있는 인간을 포함한 모든 동물을 의미할 수 있다.In the present invention, the term "individual" may mean all animals including humans who have developed or are likely to develop dental caries or periodontal disease.
본 발명에 따른 식품 조성물에서, 상기 식품의 종류는 특별히 제한되지 아니하며, 통상적인 의미에서의 식품을 모두 포함할 수 있다. 상기 물질을 첨가할 수 있는 식품의 비제한적인 예로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등을 들 수 있다. 상기 조성물을 식품 첨가물로 사용할 경우, 상기 조성물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다.In the food composition according to the present invention, the type of the food is not particularly limited, and may include foods in a conventional sense. Non-limiting examples of the food to which the substance can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, , A drink, an alcoholic beverage, and a vitamin complex. When the composition is used as a food additive, the composition may be added as it is or may be used together with other food or food ingredients, and may be suitably used according to a conventional method.
본 명세서에서 식품이란 함은 영양소를 한 가지 또는 그 이상 함유하고 있는 천연물 또는 가공품을 의미하며, 바람직하게는 어느 정도의 가공 공정을 거쳐 직접 먹을 수 있는 상태가 된 것을 의미하며, 통상적인 의미이고, 상기 식품 조성물은 식품, 식품 첨가제, 건강 기능성 식품 및 음료를 모두 포함하는 의도이다.The term " food " as used herein means a natural product or a processed product containing one or more nutrients. Preferably, the term " food " The food composition is intended to include food, food additives, health functional foods and beverages.
본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 각종 식품류, 음료, 껌, 캔디, 차, 비타민 복합제, 기능성 식품 등이 있다. 추가로, 본 발명에서 식품에는 특수영양식품(예, 조제유류, 영, 유아식 등), 식육가공품, 어육제품, 두부류, 묵류, 면류(예, 라면류, 국수류 등), 건강보조식품, 조미식품(예, 간장, 된장, 고추장, 혼합장 등), 소스류, 과자류(예, 스넥류), 유가공품(예, 발효유, 치즈 등), 기타 가공식품, 김치, 절임 식품(각종 김치류, 장아찌 등), 음료(예, 과실, 채소류 음료, 두유류, 발효음료류, 아이스크림류 등), 천연조미료(예, 라면 스프 등), 비타민 복합제, 알코올 음료, 주류 및 그 밖의 건강보조식품류를 포함하나 이에 한정되지 않는다. 상기 식품, 음료 또는 식품첨가제는 통상의 제조방법으로 제조될 수 있다.Foods to which the composition of the present invention can be added include, for example, various foods, beverages, gums, candies, tea, vitamin complexes, and functional foods. In addition, in the present invention, the food may contain special nutritional foods (e.g., crude oil, spirits, infant food, etc.), meat products, fish products, tofu, jelly, noodles (Such as soy sauce, soybean paste, hot pepper paste, mixed sauce), sauces, confectionery (eg snacks), dairy products (eg fermented milk, cheese), other processed foods, kimchi, pickled foods But are not limited to, natural flavors (eg, ramen soup, etc.), vitamin complexes, alcoholic beverages, alcoholic beverages and other health supplement foods. The food, beverage or food additive may be prepared by a conventional production method.
본 발명에 따른 건강기능식품 조성물에서 "건강기능식품"이란 건강보조의 목적으로 특정성분을 원료로 하거나 식품 원료에 들어있는 특정성분을 추출, 농축, 정제, 혼합 등의 방법으로 제조, 가공한 식품을 말하며, 상기 성분에 의해 생체 방어, 생체리듬의 조절, 질병의 방지와 회복 등 생체조절기능을 생체에 대하여 충분히 발휘할 수 있도록 설계되고 가공된 식품을 말하는 것으로서, 질병의 예방 또는 건강의 회복 등과 관련된 기능을 수행할 수 있는 것을 말한다.The term "health functional food" in the health functional food composition according to the present invention is intended to mean a food having a specific ingredient as a raw material for the purpose of health assisting or a specific ingredient contained in a food raw material prepared and processed by extraction, concentration, Refers to a food which is designed and processed so that the biological control function such as bio-defense, regulation of biorhythm, prevention and recovery of disease and the like can be sufficiently exhibited to the living body by the above components. Which is capable of performing a function.
본 발명에 따른 균주를 건강기능식품으로 사용하는 경우, 이를 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 이는 필요에 따라 선택하여 적절하게 사용될 수 있다. 또한, 첨가되는 균주들은 단독 또는 혼합하여 사용할 수 있고, 이 경우 혼합양은 그 사용 목적에 따라 적합하게 결정할 수 있다. When the strain according to the present invention is used as a health functional food, it can be added as it is or can be used together with other food or food ingredients, and can be appropriately selected and used as needed. In addition, the strains to be added can be used singly or in combination, and in this case, the mixing amount can be appropriately determined depending on the purpose of use.
또한, 본 발명에 따른 균주가 사용될 수 있는 건강기능식품의 종류에는 특별한 제한이 없다. 예컨대, 라면, 기타 면류, 음료수, 차, 드링크제, 알콜 음료, 각종 스프, 육류, 소세지, 빵, 초코렛, 캔디류, 과자류, 피자, 껌류, 아이스크림류를 포함한 낙농제품, 또는 비타민 복합제 등이 있다. 특히, 본 발명에 따른 균주는 소화관 내에서의 위산 또는 담즙염에 대한 생존력, 세포내 부착력 및 충치균 또는 치주염균에 대한 억제 효과가 우수하므로, 다양한 건강기능식품으로 제조하기 적합하다. 본 발명의 균주가 포함될 수 있는 발효유 건강기능식품으로는 예컨대, 요구르트, 칼피스, 치즈, 버터 등을 들 수 있고, 발효 제품으로는 두부, 된장, 청국장, 젤리, 김치 등을 들 수 있다. 상기 발효유 또는 발효제품은 통상적인 제조방법에서 균주만을 본 발명에 따른 균주로 대체함으로써 용이하게 제조할 수 있다.There is no particular limitation on the kind of health functional food to which the strain according to the present invention can be used. Examples include dairy products including noodles, other noodles, beverages, tea, drinks, alcoholic beverages, various soups, meats, sausages, breads, chocolates, candies, confectionery, pizza, gums and ice cream, or vitamin complexes. In particular, the strain according to the present invention is suitable for producing various health functional foods because it has excellent survival ability against gastric acid or bile salt in gastrointestinal tract, intracellular adherence, and inhibitory effect against tooth decay bacteria or periodontal bacteria. Examples of the fermented milk health food containing the strain of the present invention include yogurt, calpis, cheese, butter and the like. Examples of the fermented product include tofu, soybean paste, chungkukjang, jelly, and kimchi. The fermented milk or the fermented product can be easily produced by replacing only the strain with the strain according to the present invention in a conventional production method.
또한, 본 발명에 따른 균주는 통상의 기술자의 선택에 따라 통상적으로 건강기능식품에 함유될 수 있는 적절한 기타 보조성분과 공지의 첨가제를 혼합할 수 있다. 상기 공지의 첨가제에는 본 발명에 따른 균주와 함께 사용할 수 있는 다른 미생물도 포함된다.In addition, the strain according to the present invention may be blended with other suitable auxiliary ingredients known in the art, which may be contained in the health functional food, according to the choice of the ordinarily skilled artisan. These known additives also include other microorganisms which can be used in combination with the strain according to the present invention.
또한 본 발명의 균주는 치아 우식증 또는 치주질환의 예방 또는 개선을 목적으로 의약외품 조성물에 포함될 수 있다. Also, the strain of the present invention may be included in a quasi-drug composition for the purpose of preventing or improving dental caries or periodontal disease.
본 발명의 균주를 의약외품으로 사용할 경우, 상기 균주를 그대로 첨가하거나 다른 의약외품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합양은 사용 목적 (예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 본 발명이 의약외품 조성물로 사용되는 경우, 구강 조성물인 치약류, 구강청결제류, 구강세정제류 구강 스프레이류 등의 제형으로 제조하여 사용할 수 있다. When the strain of the present invention is used as a quasi-drug, the strain may be added as it is or may be used together with other quasi-drug components, and may be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (prevention, health or therapeutic treatment). When the present invention is used as a quasi-drug composition, it can be manufactured and used in the form of oral compositions such as dentifrices, oral cleansers, oral cleansers and oral sprays.
이하 본 발명의 이해를 돕기 위하여 바람직한 실시예 및 제제예를 제시한다. 그러나 하기 실시예 및 제제예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 이에 의해 본 발명의 내용이 한정되는 것은 아니다.Hereinafter, preferred embodiments and examples of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples and preparation examples are provided only for the purpose of easier understanding of the present invention, and thus the content of the present invention is not limited thereto.
실시예Example 1. 사용한 균주의 분리 및 사용 시료의 제조 1. Separation of used strains and preparation of samples for use
인체 및 식품 유래 유산균인 락토바실러스 살리바리우스 (L. salivarius ) MG242, 락토바실러스 루테리(L. reuteri) MG505, 락토바실러스 루테리(L. reuteri ) MG4224, L. salivarius MG4265, L. salivarius MG4293, L. salivarius MG4525, L. salivarius MG4526, L. salivarius MG4527, L. salivarius MG5183, L. reuteri MG5149, L. salivarius MG5207 및 L. salivarius MG5212 를 이용하여 실험을 수행하였다. Lactobacilli MRS (Difco, MI, USA) 배지를 사용하여 유산균주를 37℃에서 정치배양하였으며, 유산균주를 MRS 액체배지에 24시간 정치배양한 배양액을 원심분리 (4,000 × g, 4℃, 5분)한 후, 0.22 μm 필터를 이용하여 얻어진 제균된 상등액 (CFS, cell free supernatant)을 실험에 사용하였다. 항균 활성을 측정하기 위하여 한국미생물자원센터 (Korean Collection for Type Cultures, KCTC)에서 분양 받은 스트렙토코쿠스 뮤탄스 (Streptococcus mutans) KCTC3065와 포르리로모나스 진지발린스 (Porphyromonas gingivalis) KCTC5352 표준균주를 사용하였다. S. mutans는 BHI(Difco, MI, USA)배지를 사용하여 배양하였으며, P. gingivalis는 sheep blood 배지에 접종하여 37℃에서 혐기적으로 정치배양하였다. Human and food-derived lactic acid bacteria Lactobacillus salivarius (L. salivarius) MG242, Lactobacillus ruteri (L. reuteri) MG505, Lactobacillus ruteri (L. reuteri) MG422 4, L. salivarius MG4265, L. salivarius MG4293, L. salivarius MG4525, L. salivarius MG4526, L. salivarius MG4527, L. salivarius MG5183, L. reuteri MG5149, L. salivarius MG5207 And L. salivarius Experiments were conducted using MG5212. Lactobacilli MRS (Difco, MI, USA) medium was used to culture the lactic acid bacteria at 37 ° C., and the culture broth was cultured in MRS liquid medium for 24 hours. The culture broth was centrifuged (4,000 × g, 4 ° C., Afterwards, the sterilized supernatant (CFS, cell free supernatant) obtained using a 0.22 μm filter was used for the experiment. Streptococcus mutans KCTC3065 and Porphyromonas gingivalis KCTC5352 were purchased from the Korean Collection for Type Cultures (KCTC) to measure antimicrobial activity. S. mutans was cultured using BHI (Difco, MI, USA) medium and P. gingivalis was inoculated anaerobically at 37 ° C in sheep blood medium.
실시예Example 2. 2. S. S. mutansmutans 및And P. P. gingivalisgingivalis 에 대한 항균 효과 확인 Identification of antimicrobial effects against
상기 실시예 1의 Lactobacillus reuteri 3종과 Lactobacillus salivarius 9종을 이용하여 paper disc diffusion assay 방법을 통해 S. mutans 와 P. gingivalis에 대한 항균 활성을 확인하였다. 충치 유발세균을 각각의 액체 배양배지에 24시간 전 배양한 후, 새로운 고체 배양배지에 McFarland 0.5로 현탁하여 도말하였다. 도말한 고체 배양배지에 15시간 동안 MRS 배지에서 배양한 유산균주의 배양액을 10 μL씩 spot하여 37℃에서 배양한 후, 저해환을 확인하였으며, 저해환에 따른 항균 효과 확인 결과를 표 1에 나타내었다. The antimicrobial activity against S. mutans and P. gingivalis was confirmed by paper disc diffusion assay method using the Lactobacillus reuteri 3 and Lactobacillus salivarius 9 in Example 1. The cavities-induced bacteria were cultured in each liquid culture medium for 24 hours, and then suspended in McFarland 0.5 in a new solid culture medium. The culture broth of the lactic acid bacteria cultured in the MRS medium for 15 hours in the solid culture medium was incubated at 37 ° C by spotting 10 μL each, and the inhibitory rings were confirmed. The results of the antimicrobial effects of the inhibitory rings are shown in Table 1 .
[표 1][Table 1]
상기 표 1에 나타낸 바와 같이, 모든 L. reuteri 와 L. salivarius 가 S. mutans 와 P. gingivalis 에 대한 억제활성을 나타내는 것은 아님을 확인하였고, 충치균 및 치주염균 모두에 억제효과를 보인 균주로 MG242, MG505, MG4265, MG4293, MG4526, MG4527, MG5183, MG5207, MG5212 균주 총 9종을 확인하였다. As shown in Table 1 above, all of L. reuteri and L. salivarius MG250, MG4265, MG4293, MG4526, MG4527, MG5183, MG5207, MG5212, and MG5212, which inhibited both mucus and periodontal bacteria, were not found to exhibit inhibitory activity against S. mutans and P. gingivalis . A total of 9 species were identified.
S. mutans와 P. gingivalis에 저해환을 보인 유산균주를 이용하여 추가적으로 S. mutans에 대한 무세포 상등액과 배양액에 대한 항균효과를 확인하였다. 배양여액를 통한 항균실험은 유산균주의 제균된 상등액인 무세포 상등액 (CFS)을 BHI 액체배지에 10% 첨가한 후, S. mutans를 105 CFU/mL 되도록 접종하여 수행하였다. 혼합배양을 통한 항균실험은 유산균주와 S. mutans를 혼합배지 (MRS 액체배지와 BHI 액체배지를 1:1 (v/v)로 혼합)에 균의 농도가 최종적으로 105 CFU/mL 되도록 각각 접종하여 수행하였다. 각 항균효과 확인 실험은 8시간 동안 37℃에서 혐기적으로 정치배양 후, erythromycin (0.3 μL/mL)를 도포한 BHI 고체배지에 도말하여 S. mutans의 생균수를 확인하는 방식으로 수행하였고, 그 결과를 도 1에 나타내었다. The antimicrobial activity of S. mutans against the cell-free supernatant and the culture medium was further confirmed by using lactic acid bacteria showing inhibitory effects on S. mutans and P. gingivalis . The antimicrobial activity of the culture filtrate was determined by adding 10% of a cell-free supernatant (CFS), which is a sterilized supernatant of lactic acid bacteria, to BHI liquid medium and then inoculating S. mutans to 10 5 CFU / mL. The antimicrobial activity of mixed cultures was determined by mixing lactic acid bacteria and S. mutans in a mixed medium (MRS liquid medium and BHI liquid medium mixed at 1: 1 ( v / v )) to a final concentration of 10 5 CFU / mL Inoculation. Each antimicrobial effect test was carried out by incubating for 8 hours at 37 ° C anaerobically and then plated on a BHI solid medium coated with erythromycin (0.3 μL / mL) to determine the viable count of S. mutans . The results are shown in Fig.
도 1에 나타낸 바와 같이, Lactobacillus salivarius MG242, L. reuteri MG505, L. salivarius MG4293, L. salivarius MG4527, L. salivarius MG5183 5종은 무세포 상등액과 배양액을 접종하였을 때에도 S. mutans 에 높은 활성을 보임을 확인하였다. 상기와 같이 우수한 활성을 나타내는 균주들을 한국생명공학원에 기탁하였으며, Lactobacillus salivarius MG242 기탁번호: KCTC 18554P, L. reuteri MG505 기탁번호: KCTC 13523BP, L. salivarius MG4293 기탁번호: KCTC 13727BP, L. salivarius MG4527 기탁번호: KCTC 13728BP, L. salivarius MG5183 기탁번호: KCTC 13729BP 로 기탁번호를 부여받았다. As shown in Figure 1, Lactobacillus salivarius MG242, MG505 L. reuteri, L. salivarius MG4293, MG4527 L. salivarius, L. salivarius MG5183 5 species even when inoculated with cell-free supernatant and the culture S. mutans In the case of the present invention. Lactobacillus salivarius MG242 Accession number: KCTC 18554P, L. reuteri MG505 Accession number: KCTC 13523BP, L. salivarius MG4293 Accession number: KCTC 13727BP, L. salivarius MG4527 Deposit No.: KCTC 13728BP, L. salivarius MG5183 Accession number: KCTC 13729BP.
실시예Example 3. 3. 선별 균주의 Selective strain 내산성Acid resistance 및 And 내담즙성My bile 확인 Confirm
유산균이 프로바이오틱스로 이용되기 위해서는 안전성과 안정성을 갖춰야 한다. 특히 유산균을 경구로 투여하는 경우, 위액과 각종 효소가 존재하는 위를 통과하고, 담즙이 존재하는 십이지장을 거쳐 최종 목적 부위인 장에 도달해야 기능적인 효과를 나타낼 수 있으므로, 유산균의 내산성 및 내담즙성은 프로바이오틱스로 활용하기 위한 중요한 지표이다. 따라서 상기 실시예 2에서 선별된 유산균주 5종이 장내 환경과 같은 산성 및 담즙염에 대해서 내산성 및 내담즙성을 가져 생균력을 유지하는지 여부를 확인하기 위한 실험을 수행하였다. 구체적으로 유산균주를 18시간 동안 배양한 후, 원심분리 (4,000 × g, 4℃, 5분)하여 phosphate-buffered saline (PBS, pH 7)에 2회 세척하였고, OD600 1.0으로 조정하여 각각 산성과 담즙염에 대한 내성 실험에 사용하였다. 산성에 대한 내성을 확인하기 위하여 유산균 희석액 1 mL를 9 mL PBS (pH 2와 7)에 첨가 후 진탕한 뒤 37℃에서 3시간 배양한 후 생균수를 확인하였다. 담즙염 내성은 0~1% oxgall (Difco, MI, USA)을 포함한 MRS 배지에 유산균 희석액을 1% 접종하고 37℃에 24시간 배양한 후 생균수를 확인하는 방법을 통해 확인하고 그 결과를 표 2에 나타내었다. In order for lactobacillus to be used as probiotics, it must be safe and stable. In particular, when the lactic acid bacteria are administered orally, the lactic acid bacteria can pass through the gastric juice and the stomach where the various enzymes are present and reach the target site through the duodenum in which the bile is present. Therefore, Sex is an important indicator for utilizing as probiotics. Therefore, experiments were carried out to confirm whether the 5 kinds of lactic acid bacteria selected in Example 2 had acid resistance and bile salt resistance against acidic and bile salts such as intestinal environment and maintained viable bacteria. After the specific incubation for 18 hours, the Lactobacillus week, centrifuged (4,000 × g, 4 ℃, 5 minutes) to phosphate-buffered saline (PBS, pH 7) in it was washed twice, each acid to adjust to OD 600 1.0 And bile salts. To confirm the tolerance to acidity, 1 mL of the diluted lactic acid bacteria was added to 9 mL of PBS (pH 2 and 7), shaken, and incubated at 37 ° C for 3 hours. The bile salt tolerance was determined by inoculating 1% of the lactic acid bacteria diluted with MRS medium containing 0-1% oxgall (Difco, MI, USA) and culturing at 37 ° C for 24 hours. Respectively.
[표 2][Table 2]
표 2에 나타낸 바와 같이 산성에 대한 내성 실험의 결과, 위액 환경에 해당하는 pH 2에서 모든 균주가 102 CFU/mL 이상의 생균수를 나타냈으며, MG505 (5.86 log CFU/mL) 가 가장 높은 생균수를 보이는 것을 확인하였다. 체내 위액의 pH는 대략 3.0으로 유지되며, 일반적으로 미생물이 위를 통과하는 시간은 3시간이기에 pH 3에서 3시간 이상 생균수를 유지하면 산성에 높은 내성을 보이는 것으로 판단할 수 있다. 프로바이오틱스로 사용되는 여러 균주들이 pH 2에서 일반적으로 104 CFU/mL 이하의 생균수를 보이는 것으로 알려져 있으며, 본 연구에서 선별된 유산균주의 경우 특히 MG505, MG4293, MG4527 이 산성에 대해 우수한 내성능력을 가지고 있는 것을 확인할 수 있다.As shown in Table 2, all strains showed a viable cell count of 10 2 CFU / mL or more at pH 2 corresponding to the stomach environment, and MG505 (5.86 log CFU / mL) showed the highest viable cell count Respectively. The pH of the body's gastric juice is maintained at about 3.0, and the time for the microorganism to pass through the stomach is usually 3 hours. Therefore, if the viable cell count is maintained at pH 3 for more than 3 hours, Several strains used as probiotics are known to have viable cell counts of less than 10 4 CFU / mL at pH 2, and MG505, MG4293 and MG4527, especially in the case of selected lactic acid bacteria in this study, have excellent resistance to acid .
또한 통상 담즙염에 대한 내성을 확인하기 위한 0.3% 의 담즙염 농도에서 종래 유산균들이 4 log CFU/mL 이하로 담즙염에 민감한 것과 달리, 본원 발명의 5종의 균주는 이보다 높은 1% 담즙염 농도에서도 평균 8.01 log CFU/mL의 매우 높은 생균수를 보여, 담즙염에 대해 매우 우수한 내성을 보이는 것을 확인할 수 있다.Unlike conventional lactic acid bacteria which are sensitive to bile salt at a concentration of less than 4 log CFU / mL at a concentration of 0.3% of bile salt for confirming resistance to bile salt, the five strains of the present invention have higher 1% bile salt concentration , The average number of viable cells was 8.01 log CFU / mL, indicating that the cells exhibited excellent resistance to bile salts.
실시예Example 4. 선별된 4. Selected 유산균주의Lactic acid bacteria 자가응집능Self-aggregating ability 확인 Confirm
장내 세포 내 부착능력을 간접적으로 확인하기 위하여 자가 응집력 (autoaggregation) 을 확인하는 실험을 수행하였다. MRS 배지에 유산균을 전 배양한 배양액을 OD600 1.0으로 조정하여 새로운 5 mL MRS 배지에 1% 접종한 뒤, 18시간 배양하여 실험에 사용하였다. 배양한 유산균은 원심분리 (4,000 × g, 4℃, 5분)한 후, PBS에 2번 세척하였고, OD600 1.0으로 조정하여 균주 현탁액 5 mL을 10초간 진탕한 뒤 5시간 동안 방치하면서 자가 응집능을 확인하였다. 실험 시작 직후 (A0)와 5시간 후 (A), 각각 0.1 mL의 상등액을 취해 0.9 mL PBS와 혼합한 뒤 600 nm에서 흡광도를 측정 (A0, A)하였고, 다음 계산식에 따라 자가 응집능을 계산하고 그 결과를 도 2에 나타내었다. Experiments were performed to confirm the autoaggregation in order to indirectly confirm intracellular adhesion ability. The culture medium in which the lactic acid bacteria were pre-cultured in the MRS medium was adjusted to OD 600 1.0, inoculated 1% in the fresh 5 mL MRS medium, and cultured for 18 hours. The cultured lactic acid bacteria were centrifuged (4,000 × g, 4 ° C., 5 minutes), washed twice with PBS, adjusted to OD 600 1.0, and 5 mL of the strain suspension was shaken for 10 seconds, . Immediately after the start of the experiment (A0) and after 5 hours (A), 0.1 mL of the supernatant was mixed with 0.9 mL PBS, and the absorbance was measured at 600 nm (A0, A) The results are shown in Fig.
자가 응집능 (%) = (A0A) / A0 × 100Self-aggregating ability (%) = (A0A) /
도 2에 나타낸 바와 같이, MG4293, MG4527 균주가 각각 74.14 ± 2.18%, 65.78 ± 1.39%로 가장 높은 자가응집 능력을 보였으며, 선별된 5 균주에 대한 자가응집능의 평균은 61.64%였다. 유산균의 in vitro 상의 자가응집능은 in vivo 상의 부착능과도 연관되어 있는 것으로 보고되어 있으므로, 본원 발명의 5종의 균주들은 모두 자가응집능 및 부착능이 우수함을 확인하였다. As shown in FIG. 2, MG4293 and MG4527 showed the highest self-aggregating ability of 74.14 ± 2.18% and 65.78 ± 1.39%, respectively, and the average of the self-aggregating ability of 5 selected strains was 61.64%. It has been reported that the in vitro self-aggregating ability of lactic acid bacteria is also related to the in vivo adhesion ability, so that all of the five strains of the present invention have excellent self-aggregating ability and adhesion ability.
실시예Example 5 혼합 균주의 5 mixed strains S. S. mutansmutans 에 대한 항균 효과 확인 Identification of antimicrobial effects against
Lactobacillus salivarius MG242, L. reuteri MG505, L. salivarius MG4293, L. salivarius MG4527, L. salivarius MG5183 5종 혼합 균주의 무세포 상등액 (CFS, cell free supernatant)을 및 배양액을 이용하여 S. mutans 에 대한 항균 효과를 확인하였다. The cell free supernatant (CFS) of five mixed strains of Lactobacillus salivarius MG242, L. reuteri MG505, L. salivarius MG4293, L. salivarius MG4527, and L. salivarius MG5183 and S. mutans Was confirmed.
무세포 상등액 (CFS) 은 상기 균주들을 MRS 액체 배지에서 24시간 정치배양 한 후, 배양액을 4,000 × g, 4℃, 5분 조건으로 원심분리하는 단계, 이를 0.22 μm 필터로 여과하는 단계를 거쳐 제조하였다. 또한 혼합 배양액 (cell mixture) 의 항균 효과를 확인하기 위하여 5종 균주 (105 CFU/mL) 각각의 배양액 5ml 를 혼합하여 혼합 배양액을 제조하였다. 혼합 균주의 항균 효과 확인을 위하여 실험에 사용한 실험군은 하기와 같다. The cell-free supernatant (CFS) was prepared by culturing the above strains in an MRS liquid medium for 24 hours, centrifuging the culture at 4,000 × g, 4 ° C., and 5 minutes, and filtering it with a 0.22 μm filter Respectively. In order to confirm the antimicrobial effect of the cell mixture, 5 ml of the culture solution of 5 kinds of strains (10 5 CFU / ml) were mixed to prepare a mixed culture. The experimental group used for the experiment to confirm the antibacterial effect of the mixed strains is as follows.
실험군 1 (혼합 무세포 상등액): 5종 균주의 무세포 상등액을 각각 동일 부피비로 혼합 Experimental group 1 (mixed cell-free supernatant): The cell-free supernatant of the 5-type strain was mixed at the same volume ratio
실험군 2 (혼합 배양액): 5종 균주 각각의 세포 배양액을 동일 부피비로 혼합Experimental group 2 (mixed culture): Five kinds of cell cultures were mixed at the same volume ratio
실험군 3 (무세포 상등액 및 배양액 혼합): 5종 균주 각각의 무세포 상등액 및 세포 배양액을 동일 부피비로 혼합Experimental group 3 (cell-free supernatant and culture solution mixture): 5-cell strain The cell-free supernatant and the cell culture were mixed at the same volume ratio
상기 5종 혼합 균주의 혼합 무세포 상등액 또는 혼합 배양액과 S. mutans 를 혼합 배지 (MRS 액체배지와 BHI 액체배지를 1:1 (v/v)로 혼합)에 균의 농도가 최종적으로 105 CFU/mL 되도록 각각 접종하였다. 항균 효과 확인을 위해서 37℃ 에서 8시간동안 혐기적으로 배양한 후, 에리스로마이신 0.3 μL/mL를 도포한 BHI 고체배지에 도말하여 S. mutans 를 계수하였으며, 그 결과를 도 3에 나타내었다. The bacterial cell-free supernatant or mixed culture of the above 5 strains and the S. mutans were mixed with the MRS liquid medium and the BHI liquid medium at a ratio of 1: 1 ( v / v ), and finally the bacterial concentration reached 10 5 CFU / mL, respectively. To confirm the antimicrobial effect, the cells were anaerobically cultured at 37 ° C for 8 hours, and then plated on a BHI solid medium coated with 0.3 μL / mL of erythromycin to obtain S. mutans And the results are shown in FIG.
도 3에 나타낸 바와 같이, 미처리 대조군 대비 혼합 무세포 상등액, 혼합 배양액 및 이들의 혼합물을 처리한 실험군 모두에서 대조군 대비 효과적인 S. mutans 억제 효과를 확인하였다. 이러한 결과를 통해 본원 발명의 Lactobacillus salivarius MG242, L. reuteri MG505, L. salivarius MG4293, L. salivarius MG4527, L. salivarius MG5183 5종 균주가 모두 S. mutans 에 대한 우수한 항균효과를 나타내며, 특히 이들 균주의 혼합 배양액을 이용하는 경우 우수한 항균 효과를 나타냄을 확인하였다. As shown in Fig. 3, in both the experimental group treated with the mixed cell-free supernatant, the mixed culture, and the mixture thereof compared to the untreated control, S. mutans Inhibitory effect was confirmed. These results indicate that the five strains of Lactobacillus salivarius MG242, L. reuteri MG505, L. salivarius MG4293, L. salivarius MG4527 and L. salivarius MG5183 of the present invention are all S. mutans , And showed excellent antimicrobial effect when mixed cultures of these strains were used.
Claims (11)
상기 락토바실러스 살리바리우스 MG4293 균주 및 락토바실러스 살리바리우스 MG4527 균주는 pH 2 내지 pH 4 에서 내산성 및 0.1 내지 1.5% (w/v) 담즙염에 내담즙성을 갖는 것을 특징으로 하는, 충치균 및 치주염균 억제용 항균 조성물.
A culture or culture thereof or a cell-free supernatant thereof, which comprises a strain of Lactobacillus salivarius MG4293 (Accession No .: KCTC 13727BP) and a strain of Lactobacillus salivarius MG4527 (Accession No .: KCTC 13728BP)
Wherein said Lactobacillus salivarius MG4293 strain and Lactobacillus salivarius MG4527 strain have bile acid resistance to acid tolerance and 0.1 to 1.5% (w / v) bile salt at pH 2 to pH 4, / RTI >
The composition according to claim 1, which is selected from the group consisting of Lactobacillus luteri MG505 (Accession No .: KCTC 13523BP), Lactobacillus salivarius MG242 (Accession No .: KCTC 18554P) and Lactobacillus salivarius MG5183 (Accession No .: KCTC 13729BP) The antimicrobial composition for inhibiting cavities and periodontitis bacteria according to any one of claims 1 to 3, further comprising a culture solution or a cell-free supernatant thereof.
The antimicrobial composition according to claim 1, wherein the decidua is Streptococcus mutans .
The antimicrobial composition according to claim 1, wherein the periodontal bacteria is Porphyromonas gingivalis .
The antimicrobial composition according to claim 1, wherein the strain has an autoaggregation ability.
The antifungal and antimicrobial agent for inhibiting periodontitis bacteria according to claim 1, which comprises a culture of Lactobacillus salivarius MG4293 strain (Accession No .: KCTC 13727BP) and Lactobacillus salivarius MG4527 strain (Accession No .: KCTC 13728BP) Composition.
상기 락토바실러스 살리바리우스 MG4293 균주 및 락토바실러스 살리바리우스 MG4527 균주는 pH 2 내지 pH 4 에서 내산성 및 0.1 내지 1.5% (w/v) 담즙염에 내담즙성을 갖는 것을 특징으로 하는, 치아 우식증 및 치주질환 예방 또는 치료용 약학적 조성물.
A culture or culture thereof or a cell-free supernatant thereof, which comprises a strain of Lactobacillus salivarius MG4293 (Accession No .: KCTC 13727BP) and a strain of Lactobacillus salivarius MG4527 (Accession No .: KCTC 13728BP)
Wherein said Lactobacillus salivarius MG4293 strain and Lactobacillus salivarius MG4527 strain have bile acid resistance to acid tolerance and 0.1 to 1.5% (w / v) bile salt at pH 2 to pH 4, and dental caries and periodontal disease A pharmaceutical composition for preventing or treating.
상기 락토바실러스 살리바리우스 MG4293 균주 및 락토바실러스 살리바리우스 MG4527 균주는 pH 2 내지 pH 4 에서 내산성 및 0.1 내지 1.5% (w/v) 담즙염에 내담즙성을 갖는 것을 특징으로 하는, 치아 우식증 및 치주질환 예방 또는 개선용 건강기능식품 조성물.
A culture or culture thereof or a cell-free supernatant thereof, which comprises a strain of Lactobacillus salivarius MG4293 (Accession No .: KCTC 13727BP) and a strain of Lactobacillus salivarius MG4527 (Accession No .: KCTC 13728BP)
Wherein said Lactobacillus salivarius MG4293 strain and Lactobacillus salivarius MG4527 strain have bile acid resistance to acid tolerance and 0.1 to 1.5% (w / v) bile salt at pH 2 to pH 4, and dental caries and periodontal disease Prevention or amelioration.
상기 락토바실러스 살리바리우스 MG4293 균주 및 락토바실러스 살리바리우스 MG4527 균주는 pH 2 내지 pH 4 에서 내산성 및 0.1 내지 1.5% (w/v) 담즙염에 내담즙성을 갖는 것을 특징으로 하는, 치아 우식증 및 치주질환 예방 또는 개선용 의약외품 조성물. A culture or culture thereof or a cell-free supernatant thereof, which comprises a strain of Lactobacillus salivarius MG4293 (Accession No .: KCTC 13727BP) and a strain of Lactobacillus salivarius MG4527 (Accession No .: KCTC 13728BP)
Wherein said Lactobacillus salivarius MG4293 strain and Lactobacillus salivarius MG4527 strain have bile acid resistance to acid tolerance and 0.1 to 1.5% (w / v) bile salt at pH 2 to pH 4, and dental caries and periodontal disease A quasi-composition for prevention or improvement.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180156663A KR102001074B1 (en) | 2018-12-07 | 2018-12-07 | Lactobacillus having anticariogenic activities and composition comprising the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180156663A KR102001074B1 (en) | 2018-12-07 | 2018-12-07 | Lactobacillus having anticariogenic activities and composition comprising the same |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190082644A Division KR102210092B1 (en) | 2019-07-09 | 2019-07-09 | Lactobacillus reuteri MG505 having anticariogenic activities and composition comprising the same |
| KR1020190082670A Division KR102230517B1 (en) | 2019-07-09 | 2019-07-09 | Lactobacillus salivarius having anticariogenic activities and composition comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102001074B1 true KR102001074B1 (en) | 2019-07-18 |
Family
ID=67469410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180156663A Expired - Fee Related KR102001074B1 (en) | 2018-12-07 | 2018-12-07 | Lactobacillus having anticariogenic activities and composition comprising the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102001074B1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210041220A (en) * | 2019-10-07 | 2021-04-15 | 선문대학교 산학협력단 | A cosmetic composition comprising microalgae-derived peptide |
| CN113308389A (en) * | 2020-10-12 | 2021-08-27 | 镇江市天益生物科技有限公司 | Lactobacillus salivarius and application thereof |
| WO2021194011A1 (en) * | 2020-03-23 | 2021-09-30 | 숙명여자대학교산학협력단 | Probiotics for prevention or treatment of oral disease and food composition comprising same for prevention or treatment of oral disease |
| CN115960741A (en) * | 2022-05-31 | 2023-04-14 | 青岛蔚蓝生物股份有限公司 | A strain of Lactobacillus saliva associated with prevention or treatment of dental caries and periodontal disease |
| KR102704451B1 (en) * | 2023-12-21 | 2024-09-06 | 이형도 | Lactic acid bacteria composition with significantly increased cavity prevention effect |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040111434A (en) * | 2002-03-29 | 2004-12-31 | 가부시키가이샤 프렌테 인터내셔날 | Vital cell preparations containing lactic acid bacterium as the active ingredient and lactic acid bacterium-containing foods |
| KR101261172B1 (en) * | 2004-06-14 | 2013-05-09 | 바이오가이아 에이비 | Selection and use of lactic acid bacteria for reducing dental caries and bacterial causing dental caries |
| KR20160144248A (en) | 2015-06-08 | 2016-12-16 | 강릉원주대학교산학협력단 | Enterococcus faecium MSS2 capable of fermenting at room temperature and composition for comprising the same |
| KR20170029106A (en) | 2015-09-07 | 2017-03-15 | 이상수 | Dentifrice composition comprising extracts of fermented herb |
| KR20180093356A (en) | 2017-02-13 | 2018-08-22 | 서울대학교산학협력단 | A novel Lactobacillus salivarius and anti-bacterial use of the same |
-
2018
- 2018-12-07 KR KR1020180156663A patent/KR102001074B1/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040111434A (en) * | 2002-03-29 | 2004-12-31 | 가부시키가이샤 프렌테 인터내셔날 | Vital cell preparations containing lactic acid bacterium as the active ingredient and lactic acid bacterium-containing foods |
| KR101261172B1 (en) * | 2004-06-14 | 2013-05-09 | 바이오가이아 에이비 | Selection and use of lactic acid bacteria for reducing dental caries and bacterial causing dental caries |
| KR20160144248A (en) | 2015-06-08 | 2016-12-16 | 강릉원주대학교산학협력단 | Enterococcus faecium MSS2 capable of fermenting at room temperature and composition for comprising the same |
| KR20170029106A (en) | 2015-09-07 | 2017-03-15 | 이상수 | Dentifrice composition comprising extracts of fermented herb |
| KR20180093356A (en) | 2017-02-13 | 2018-08-22 | 서울대학교산학협력단 | A novel Lactobacillus salivarius and anti-bacterial use of the same |
Non-Patent Citations (1)
| Title |
|---|
| 치아우식 유발 Streptococcus mutans와 Streptococcus sobrinus 에 대한 유산균의 생장억제 효과 및 요구르트의 Probiotics 효능(Kor J Oral Maxillofac Pathol 2009;33(3):167-174) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210041220A (en) * | 2019-10-07 | 2021-04-15 | 선문대학교 산학협력단 | A cosmetic composition comprising microalgae-derived peptide |
| KR102249252B1 (en) | 2019-10-07 | 2021-05-07 | 선문대학교 산학협력단 | A cosmetic composition comprising microalgae-derived peptide |
| WO2021194011A1 (en) * | 2020-03-23 | 2021-09-30 | 숙명여자대학교산학협력단 | Probiotics for prevention or treatment of oral disease and food composition comprising same for prevention or treatment of oral disease |
| CN113308389A (en) * | 2020-10-12 | 2021-08-27 | 镇江市天益生物科技有限公司 | Lactobacillus salivarius and application thereof |
| CN113308389B (en) * | 2020-10-12 | 2022-06-14 | 镇江市天益生物科技有限公司 | Lactobacillus salivarius and application thereof |
| CN115960741A (en) * | 2022-05-31 | 2023-04-14 | 青岛蔚蓝生物股份有限公司 | A strain of Lactobacillus saliva associated with prevention or treatment of dental caries and periodontal disease |
| KR102704451B1 (en) * | 2023-12-21 | 2024-09-06 | 이형도 | Lactic acid bacteria composition with significantly increased cavity prevention effect |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102001074B1 (en) | Lactobacillus having anticariogenic activities and composition comprising the same | |
| KR102028744B1 (en) | Lactobacillus plantarum HY7717 strain having immune-enhancing activity, antioxidative activity and digestive fluid resistance and use thereof | |
| JP5718917B2 (en) | Novel Lactobacillus plantarum and composition containing the same | |
| KR101750468B1 (en) | Composition comprising Lactobacillus fermentum MG901 or Lactobacillus plantarum MG989 | |
| KR101638984B1 (en) | Nano-Sized Lactic Acid Bacteria from Kimchi | |
| KR102217525B1 (en) | Probiotics for prevention or treatment of periodontitis and use thereof | |
| KR101768678B1 (en) | Bifidobacterium longum ssp. infantis BI9988 isolated from Korean longevity village and having high nutraceutical activities | |
| HU228050B1 (en) | Strain of bacteria of the species lactobacillus paracasei subsp. paracasei, composition thereof for use in food and product containing said strain | |
| JP2008179601A (en) | Cosmetic composition containing bacterium of genus lactobacillus | |
| KR102479732B1 (en) | Limosilactobacillus reuteri MG5458 strain and composition for preventing, improving or treating alcoholic fatty liver comprising the same | |
| KR102230517B1 (en) | Lactobacillus salivarius having anticariogenic activities and composition comprising the same | |
| JP5337535B2 (en) | NK activity enhancer | |
| KR101743044B1 (en) | The Functional Health Food For Improving The Intestine Function and Environment and Enhencing Immunity | |
| JP2018177703A (en) | Toll-like receptor 2 activating composition | |
| KR20200018532A (en) | Lactobacillus sp. strain having inhibitory effect against microorganisms causing vaginosis uses thereof | |
| KR20180040906A (en) | A composition comprising poly-gamma glutamic acid for protecting and treating vaginosis disease and the use thereof | |
| KR20230057194A (en) | Lactobacillus brevis MG5311 strain and composition for preventing, improving or treating alcoholic fatty liver comprising the same | |
| KR100865075B1 (en) | Novel Lactobacillus SM1 Strains with Excellent Intestinal Settleability and Probiotics Produced by Them | |
| KR102210092B1 (en) | Lactobacillus reuteri MG505 having anticariogenic activities and composition comprising the same | |
| AU2019416609B2 (en) | Kimchi for preventing or treating helicobacter pylori-associated diseases | |
| JP2010209015A (en) | Composition for anti-allergy, and anti-allergic agent and anti-allergic food containing the same | |
| KR102133473B1 (en) | A composition as a prebiotic for improving intestinal microflora containing sweet potato vines | |
| KR102217518B1 (en) | Probiotics for prevention or treatment of periodontitis and use thereof | |
| JP7408070B2 (en) | Composition for enhancing or improving immunity containing Bifidobacterium bifidum | |
| KR102772627B1 (en) | Mixed bifidobacterium strains with excellent productivity and anti-inflammatory activity, and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20181207 |
|
| PA0201 | Request for examination | ||
| PA0302 | Request for accelerated examination |
Patent event date: 20190110 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination Patent event date: 20181207 Patent event code: PA03021R01I Comment text: Patent Application |
|
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20190201 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20190621 |
|
| A107 | Divisional application of patent | ||
| PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 20190709 Patent event code: PA01071R01D |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20190711 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20190711 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20220630 Start annual number: 4 End annual number: 4 |
|
| PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20240422 |